Zymeworks INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
ZYME
Zymeworks INCActivist investor EcoR1 Capital, LLC, and its affiliates, now beneficially own 30.7% of Zymeworks Inc. common stock, with an EcoR1 employee appointed Acting Chief Investment Officer.
NASDAQ
ZYME
Zymeworks INCSCHEDULE 13D: EcoR1 Capital Significantly Boosts Zymeworks Stake to Over 30% Through Warrant Exercise
EcoR1 Capital, LLC and its affiliates have substantially increased their beneficial ownership in Zymeworks Inc. to 30.7% of outstanding common stock following the full exercise of pre-funded warrants.
NASDAQ
ZYME
Zymeworks INCSCHEDULE 13D/A: EcoR1 Capital Boosts Zymeworks Stake to 25.4%, Signaling Activist Intent and Board Influence
EcoR1 Capital, along with Oleg Nodelman, has increased its beneficial ownership in Zymeworks Inc. to 25.4%, asserting significant influence through board representation and a substantial investment in common stock and pre-funded warrants.
NASDAQ
ZYME
Zymeworks INCInvestment firm EcoR1 Capital, along with its affiliates, has increased its beneficial ownership in Zymeworks Inc. to 24.2% and secured two board seats, signaling an active investment approach.
NASDAQ
ZYME
Zymeworks INCInvestment firm EcoR1 Capital, along with its affiliates, has increased its beneficial ownership in Zymeworks Inc. to 22.8% and secured a board seat for its manager, Oleg Nodelman, signaling a deeper strategic involvement.
NASDAQ
ZYME
Zymeworks INCEcoR1 Capital, LLC and its affiliates have increased their beneficial ownership in Zymeworks Inc. to 22.4% of outstanding common stock, reiterating their belief in the company's undervaluation and potential for strategic influence.